A large number of SLE patients possess an ongoing production of type I interferons and subsequently an increased expression of type I interferon regulated genes, termed IFN-signature, which correlates with autoantibodies and disease activity (126–128). The gene discussed is IFNA1; the disease is systemic lupus erythematosus.